STERIS (NYSE:STE) Posts Earnings Results, Misses Expectations By $0.01 EPS

STERIS (NYSE:STE - Get Free Report) released its quarterly earnings results on Wednesday. The medical equipment provider reported $2.32 EPS for the quarter, missing analysts' consensus estimates of $2.33 by ($0.01), Zacks reports. STERIS had a return on equity of 13.91% and a net margin of 8.66%. STERIS updated its FY 2025 guidance to 9.050-9.150 EPS.

STERIS Trading Down 1.0 %

STE traded down $2.31 during trading on Friday, reaching $223.13. The company had a trading volume of 682,890 shares, compared to its average volume of 513,142. The firm's 50-day simple moving average is $212.57 and its 200 day simple moving average is $224.51. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.55 and a current ratio of 2.13. The company has a market cap of $22.03 billion, a price-to-earnings ratio of 47.37 and a beta of 0.84. STERIS has a 12-month low of $197.82 and a 12-month high of $248.24.

STERIS Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 21st. Investors of record on Thursday, February 20th will be given a $0.57 dividend. The ex-dividend date of this dividend is Thursday, February 20th. This represents a $2.28 dividend on an annualized basis and a dividend yield of 1.02%. STERIS's dividend payout ratio (DPR) is 48.41%.

Insider Buying and Selling at STERIS

In other news, SVP Cary L. Majors sold 1,682 shares of the business's stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $217.32, for a total transaction of $365,532.24. Following the sale, the senior vice president now owns 11,372 shares in the company, valued at $2,471,363.04. The trade was a 12.88 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 1.14% of the company's stock.

Wall Street Analysts Forecast Growth

STE has been the topic of several recent analyst reports. JMP Securities reissued a "market outperform" rating and set a $265.00 target price on shares of STERIS in a report on Thursday. Needham & Company LLC restated a "hold" rating on shares of STERIS in a report on Friday, November 8th. StockNews.com lowered STERIS from a "strong-buy" rating to a "buy" rating in a report on Tuesday, October 29th. Stephens reissued an "overweight" rating and issued a $240.00 price target on shares of STERIS in a report on Thursday. Finally, Piper Sandler lifted their price objective on shares of STERIS from $260.00 to $265.00 and gave the stock an "overweight" rating in a research note on Monday, February 3rd. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $258.75.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.